Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice

Blood

Volumn 90, Issue 4, 1997, Pages 1527-1534

  Carmeliet, Peter ^b   Stassen, Jean Marie ^b   Van Vlaenderen, Ilse ^b   Meidell, Robert S ^b   Collen, Désiré ^a   Gerard, Robert D ^b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADENOVIRUS; ANIMAL CELL; ARTICLE; BLOOD CHEMISTRY; BLOOD CLOT LYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; EXPRESSION VECTOR; FIBRINOLYSIS; GENE OVEREXPRESSION; GENE TRANSFER; GENOTYPE; HUMAN; HUMAN CELL; MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENE;

EID: 0030861006     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.4.1527     Document Type: Article

References (53)

1. Juhan-Vague I,Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D: Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 57:67, 1987
2. Aoki N: Hemostasis associated with abnormalities of fibrinolysis. Blood Rev 3:11, 1989
3. Gerard RD, Meidell RS: Regulation of tissue plasminogen activator expression. Ann Rev Physiol 51:245, 1989
4. Collen D, Lijnen HR: Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78:3114, 1991
5. Schneiderman J, Loskutoff DJ: Plasminogen activator inhibitors. Trends Cardiovasc Med 1:99, 1991
6. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D: Complete deficiency of plasminogen activator inhibitor type 1 due to frameshift mutation. N Engl J Med 327:1729, 1992
7. Schleef RR, Higgins DL, Pillemer E, Levitt LJ: Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 83:1747, 1989
8. Booth NA, Wijngaards G, Grieve JHK: A new life-long hemorrhagic disorder due to excess plasminogen activator. Blood 61:267, 1983
9. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368:419, 1994
10. Carmeliet P, De Clerq C, Janssens S, Pollefeyt S, Bouché A, Wijns S, Mulligan RC, Collen D: Biological effects of the disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 genes in mice. Ann NY Acad Sci 48:367, 1995
11. Ploplis V, Carmeliet P, Vaziradeh S, Van Vlaenderen I, Moons L, Plow E, Collen D: Effects of the disruption of the plasminogen gene on thrombosis, growth and health in mice. Circulation 92:2585, 1995
12. Bugge TH, Flick MJ, Daugherty CC, Degen JL: Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 9:794, 1995
13. Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR: Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 346:74, 1990
14. Carmeliet P, Kieckens L, Schoonjans L, Ream B, Van Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan RC: Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 92:2746, 1993
15. Carmeliet P, Stassen J-M, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, Collen D: Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis. J Clin Invest 92:2756, 1993
16. Nilsson IM, Ljungner H, Tengborn L: Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: Low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 290:1453, 1985
17. Colucci M, Paramo JA, Collen D: Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 75:818, 1985
18. Aillaud MF, Juhan-Vague I, Alessi MC, Marecal M, Vinson MF, Arnoud C, Vague PH, Collen D: Increased PA-inhibitor levels in the post-operative period. No cause and effect relation with increased cortisol. Thromb Haemost 54:466, 1985
19. Sprengers ED, Kluft C: Plasminogen activator inhibitors. Blood 69:381, 1987
20. Paramo JA, Colucci M, Collen D: Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 291:573, 1985
21. Aznar J, Estelles A, Tormo G, Sapena P, Tormo V, Blanch S, Espana F: Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 58:535, 1988
22. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck B, Wiman B: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 2:3, 1987
23. Lijnen HR, Collen D: Experimental studies in thrombolysis and fibrinolysis. Curr Opin Cardiol 8:613, 1993
24. Heras M, Cheseboro JH, Thompson PL, Fuster V: Prevention of early and late reocclusion and further strategies after coronary reperfusion, in Julian D, Köbler W, Norris RM, Swan HJC, Collen D, Verstraete M (eds): Thrombolysis in Cardiovascular Disease. Basel, Switzerland, Dekker, 1989, p 203
25. Lee SW, Kahn ML, Dichek D: Control of clot lysis by gene transfer. Trends Cardiovasc Med 2:61, 1993
26. Conte MS, Biriny LK, Miyata T, Fallon JT, Gold HK, Whittemore AD, Mulligan RCM: Efficient repopulation of denuded rabbit arteries with autologous genetically modified endothelial cells. Circulation 89:2161, 1994
27. Willard JE, Landau C, Glamann DB, Burns D, Jessen ME, Gerard RD, Meidell RS: Genetic modification of the vessel wall and evaluation of catheter-based techniques for delivery of recombinant adenovirus. Circulation 89:2190, 1994
28. Flugelman MY, Virmani R, Leon MB, Bowman RL, Dichek DA: Genetically engineered endothelial cells remain adherent and viable after stent deployment and exposure to flow in vitro. Circ Res 70:348, 1992
29. Dichek DA, Neville RF, Zwiebel JA, Freeman SM, Leon MB, Anderson WF: Seeding of intravascular stents with genetically engineered endothelial cells. Circulation 80:1347, 1989
30. Herz J, Gerard RD: Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 90:2812, 1993
31. Kopfler WP, Willard M, Betz T, Willard JE, Gerard RD, Meidell RS: Adenovirus-mediated transfer of a gene encoding human apolipoprotein A1 into normal mice increases circulating high density lipoprotein cholesterol. Circulation 90:1319, 1994
32. Kozarsky KF, McKinley DR, Austin LL, Raper SE, Stratford-Perricaudet LD, Wilson JM: In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenovirus. J Biol Chem 269:13695, 1994
33. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J: Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92:883, 1993
34. Spady DK, Cuthbert JA, Willard MN, Meidell RS: Adenovirus-mediated transfer of a gene encoding cholesterol 7α-hydroxylase into hamsters increases hepatic enzyme activity and reduces plasma total and low density lipoprotein cholesterol. J Clin Invest 96:700, 1995
35. Madison EL, Goldsmith EJ, Gerard RD, Gething MJH, Sambrook JF, Bassel-Duby RS: Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 87:3530, 1990
36. Collen D, Stassen J-M, Yasuda T, Refino C, Paoni N, Keyt B, Roskams T, Guerrero JL, Lijnen HR, Gold HK, Bennett WF: Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1 -resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 72:98, 1994
37. Shohet RV, Spitzer S, Madison EL, Bassel-Duby R, Gething MJ, Sambrook JF: Inhibitor-resistant tissue-type plasminogen activator: An improved thrombolytic agent in vitro. Thromb Haemost 71:124, 1994
38. Krishnamurti C, Keyt B, Maglasang P, Alving BM: PAI-1-resistant t-PA: Low doses prevent fibrin deposition in rabbits with increased PAI-1 activity. Blood 87:14, 1996
39. McGrory WJ, Bautista DS, Graham FL: A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5. Virology 163:614, 1988
40. Gomez-Foix AM, Coats WS, Baque S, Alam T, Gerard RD, Newgard CB: Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism. J Biol Chem 267:25129, 1992
41. Graham FL, Smiley J, Russel JWC, Nairn R: Characteristics of a human cell line transformed by human adenovirus type 5. J Gen Virol 36:59, 1977
42. Gerard RD, Meidell RS: Adenovirus vectors, in Hames BD, Glover D (eds): DNA Cloning-A Practical Approach: Mammalian Systems. Oxford, UK, Oxford, 1995, p 285
43. Alcorn JL, Gao E, Chen Q, Smith ME, Gerard RD, Mendelson CR: Genomic elements involved in transcriptional regulation of the rabbit surfactant protein-A gene. Mol Endocrinol 7:1072, 1993
44. Reido FX, Munford RS, Campbell WB, Reisch JS, Chien KR, Gerard RD: Deacylated lipopolysaccharide inhibits plasminogen activator inhibitor-1, prostacyclin, and prostaglandin E2 induction by lipopolysaccharide but not by tumor necrosis factor-α. J Immunol 144:3506, 1990
45. Shubeita HE, Cottey TL, Franke AE, Gerard RD: Mutational and immunochemical analysis of plasminogen activator inhibitor-1. J Biol Chem 265:18379, 1990
46. Eitzman DT, Krauss JC, Sheng T, Cui J, Ginsburg D: Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 87:4718, 1996
47. Stassen J-M, Vanlinthout I, Lijnen HR, Collen D: A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agents. Fibrinolysis 4:15, 1990 (suppl 2)
48. Holvoet P, Cleemput H, Collen D: Assay of human tissuetype plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost 54:684, 1985
49. Clauss A: Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 17:237, 1957
50. Dichek DA, Anderson J, Kelly AB, Hanson SR, Harker LA: Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation 93:301, 1996
51. Varley AW, Coulthard M, Meidell RS, Gerard RD, Munford RS: Inflammation induced recombinant protein expression in vivo using promoters from acute-phase protein genes. Proc Natl Acad Sci USA 92:5346, 1995
52. Lieber A, Vrancken-Peeters M-JTFD, Meuse L, Fausto N, Perkins J, Kay MA: Adenovirus-mediated urokinase gene transfer induces liver regeneration and allows for efficient retrovirus transduction of hepatocytes in vivo. Proc Natl Acad Sci USA 92:6210, 1995
53. Lijnen HR, Van Hoef B, Beelen V, Collen D. Characterization of the murine plasma fibrinolytic system. Eur J Biochem 224:863, 1995